South Korea's beauty industry, which achieved a historic trade surplus of $10 billion and became the world's second-largest exporter, is undergoing a structural transformation. The government is phasing in mandatory cosmetic safety assessments from 2028, moving the sector from marketing speed to scientific safety data. This shift will reshape supply-chain priorities for OEMs, ingredient suppliers, and brand owners targeting global markets.
Regulatory overhaul: 2028 safety assessment mandate
The Ministry of Food and Drug Safety launched a public-private consultative body on March 5 to establish detailed guidelines for the Cosmetic Safety Assessment system, set to begin phased implementation in 2028. Companies with annual production over 1 billion KRW and new products will be first required to submit safety evidence, with full compliance across all items by 2031. The system mandates toxicological data and ingredient safety documentation, aligning South Korea with US MoCRA, EU CPSR, and Chinese standards.
Market signal: End of marketing-only era
K-beauty's traditional formula—fast ODM product cycles, celebrity endorsements, and aggressive marketing—is losing ground. The new regime demands that brand owners hold verified safety dossiers, shifting competitive advantage toward companies with strong R&D and accumulated toxicological databases. Industry analysts expect this to curb brand proliferation and favor established players with in-house research capabilities.
Sourcing context: OEMs and ingredient suppliers gain strategic value
As safety data becomes a core asset, beauty OEMs and raw material suppliers will play an expanded role. Previously valued for speed and production efficiency, these partners now become critical for providing ingredient toxicity profiles and formulation safety documentation. The shift reinforces the rise of derma-cosmetic and pharmacy channels, where scientific credibility already drives purchasing decisions.
What buyers should watch
Overseas importers and distributors should verify that Korean suppliers can provide safety assessment reports (CPSR-equivalent) and raw material data sheets. The 2028 mandate means early adopters with robust documentation will have a competitive edge in US, EU, and Chinese markets. Brands lacking R&D infrastructure may face supply disruptions or delisting from regulated markets.
Source: Read the original report | Published: June 09, 2026